Loading…

Surgical Management of Small Bowel Lymphoma

Background Primary small bowel non-Hodgkin’s lymphoma is a rare disease representing 2% of small intestine malignancies. There is limited data delineating the optimal treatment for these heterogeneous tumors. We aim to examine relationships between different treatment modalities and surgical outcome...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastrointestinal surgery 2021-03, Vol.25 (3), p.757-765
Main Authors: Lu, Pamela W., Fields, Adam C., Yoo, James, Irani, Jennifer, Goldberg, Joel E., Bleday, Ronald, Melnitchouk, Nelya
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c375t-ae022689bb51768697050853734f280bc51d051cb3258f815a6bb3d5ce5fd0a53
cites cdi_FETCH-LOGICAL-c375t-ae022689bb51768697050853734f280bc51d051cb3258f815a6bb3d5ce5fd0a53
container_end_page 765
container_issue 3
container_start_page 757
container_title Journal of gastrointestinal surgery
container_volume 25
creator Lu, Pamela W.
Fields, Adam C.
Yoo, James
Irani, Jennifer
Goldberg, Joel E.
Bleday, Ronald
Melnitchouk, Nelya
description Background Primary small bowel non-Hodgkin’s lymphoma is a rare disease representing 2% of small intestine malignancies. There is limited data delineating the optimal treatment for these heterogeneous tumors. We aim to examine relationships between different treatment modalities and surgical outcomes in patients with small bowel lymphoma. Materials and Methods Patients diagnosed with stage I–III small bowel lymphoma in 2004–2015 who underwent surgery were identified in the National Cancer Database. Two cohorts were created based on systemic chemotherapy treatment status. The primary outcome was overall survival. An adjusted Cox proportional hazards model was used to evaluate the impact of treatment strategy on survival. Results 2283 patients met inclusion criteria Of these patients, 826 patients (36%) underwent surgical resection alone, and 1457 patients (64%) underwent resection with systemic chemotherapy. Chemotherapy was associated with improved overall survival in unadjusted (5-year overall survival, 55% versus 70%) and adjusted analysis (HR 0.54, 95% CI 0.47–0.63, p  
doi_str_mv 10.1007/s11605-020-04730-3
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2424097580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2498796750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-ae022689bb51768697050853734f280bc51d051cb3258f815a6bb3d5ce5fd0a53</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gAdZ8CJIdJJsvo5a_IKKhyp4C9ndbG3Zj5p0kf57U7cqePA0A_PMO8OD0DGBCwIgLwMhAjgGChhSyQCzHTQkSjKcCip2Yw-aYMr56wAdhLAAIBKI2kcDRoUQqdZDdD7t_Gye2yp5tI2dudo1q6Qtk2ltqyq5bj9clUzW9fKtre0h2ittFdzRto7Qy-3N8_geT57uHsZXE5wzyVfYOqBUKJ1lnEihhJbAQXEmWVpSBVnOSQGc5BmjXJWKcCuyjBU8d7wswHI2Qmd97tK3750LK1PPQ-6qyjau7YKhKU1BS64goqd_0EXb-SZ-FymtpBaSbyjaU7lvQ_CuNEs_r61fGwJmo9L0Kk1Uab5UGhaXTrbRXVa74mfl210EWA-EOGpmzv_e_if2E-A1e0o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2498796750</pqid></control><display><type>article</type><title>Surgical Management of Small Bowel Lymphoma</title><source>Springer Nature</source><creator>Lu, Pamela W. ; Fields, Adam C. ; Yoo, James ; Irani, Jennifer ; Goldberg, Joel E. ; Bleday, Ronald ; Melnitchouk, Nelya</creator><creatorcontrib>Lu, Pamela W. ; Fields, Adam C. ; Yoo, James ; Irani, Jennifer ; Goldberg, Joel E. ; Bleday, Ronald ; Melnitchouk, Nelya</creatorcontrib><description>Background Primary small bowel non-Hodgkin’s lymphoma is a rare disease representing 2% of small intestine malignancies. There is limited data delineating the optimal treatment for these heterogeneous tumors. We aim to examine relationships between different treatment modalities and surgical outcomes in patients with small bowel lymphoma. Materials and Methods Patients diagnosed with stage I–III small bowel lymphoma in 2004–2015 who underwent surgery were identified in the National Cancer Database. Two cohorts were created based on systemic chemotherapy treatment status. The primary outcome was overall survival. An adjusted Cox proportional hazards model was used to evaluate the impact of treatment strategy on survival. Results 2283 patients met inclusion criteria Of these patients, 826 patients (36%) underwent surgical resection alone, and 1457 patients (64%) underwent resection with systemic chemotherapy. Chemotherapy was associated with improved overall survival in unadjusted (5-year overall survival, 55% versus 70%) and adjusted analysis (HR 0.54, 95% CI 0.47–0.63, p  &lt; 0.001). Discussion Patients with small bowel lymphoma have a low five-year overall survival after surgery. Chemotherapy is associated with improved survival, although one third of patients do not receive this therapy. Several other clinical factors are identified that are also associated with overall survival, including histology subtype, margin status, age, and medical comorbidities. This information can help with prognostication and potentially aid in treatment decision-making.</description><identifier>ISSN: 1091-255X</identifier><identifier>EISSN: 1873-4626</identifier><identifier>DOI: 10.1007/s11605-020-04730-3</identifier><identifier>PMID: 32666499</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cancer therapies ; Chemotherapy ; Disease ; Duodenal Neoplasms ; Gastroenterology ; Histology ; Hospitals ; Humans ; Intestine, Small - surgery ; Lymphoma ; Lymphoma - surgery ; Medical diagnosis ; Medicine ; Medicine &amp; Public Health ; Neoplasm Staging ; Original Article ; Patients ; Proportional Hazards Models ; Rare diseases ; Retrospective Studies ; Small intestine ; Statistical analysis ; Surgery ; Surgical outcomes ; Womens health</subject><ispartof>Journal of gastrointestinal surgery, 2021-03, Vol.25 (3), p.757-765</ispartof><rights>The Society for Surgery of the Alimentary Tract 2020</rights><rights>The Society for Surgery of the Alimentary Tract 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-ae022689bb51768697050853734f280bc51d051cb3258f815a6bb3d5ce5fd0a53</citedby><cites>FETCH-LOGICAL-c375t-ae022689bb51768697050853734f280bc51d051cb3258f815a6bb3d5ce5fd0a53</cites><orcidid>0000-0003-4960-3753</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32666499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Pamela W.</creatorcontrib><creatorcontrib>Fields, Adam C.</creatorcontrib><creatorcontrib>Yoo, James</creatorcontrib><creatorcontrib>Irani, Jennifer</creatorcontrib><creatorcontrib>Goldberg, Joel E.</creatorcontrib><creatorcontrib>Bleday, Ronald</creatorcontrib><creatorcontrib>Melnitchouk, Nelya</creatorcontrib><title>Surgical Management of Small Bowel Lymphoma</title><title>Journal of gastrointestinal surgery</title><addtitle>J Gastrointest Surg</addtitle><addtitle>J Gastrointest Surg</addtitle><description>Background Primary small bowel non-Hodgkin’s lymphoma is a rare disease representing 2% of small intestine malignancies. There is limited data delineating the optimal treatment for these heterogeneous tumors. We aim to examine relationships between different treatment modalities and surgical outcomes in patients with small bowel lymphoma. Materials and Methods Patients diagnosed with stage I–III small bowel lymphoma in 2004–2015 who underwent surgery were identified in the National Cancer Database. Two cohorts were created based on systemic chemotherapy treatment status. The primary outcome was overall survival. An adjusted Cox proportional hazards model was used to evaluate the impact of treatment strategy on survival. Results 2283 patients met inclusion criteria Of these patients, 826 patients (36%) underwent surgical resection alone, and 1457 patients (64%) underwent resection with systemic chemotherapy. Chemotherapy was associated with improved overall survival in unadjusted (5-year overall survival, 55% versus 70%) and adjusted analysis (HR 0.54, 95% CI 0.47–0.63, p  &lt; 0.001). Discussion Patients with small bowel lymphoma have a low five-year overall survival after surgery. Chemotherapy is associated with improved survival, although one third of patients do not receive this therapy. Several other clinical factors are identified that are also associated with overall survival, including histology subtype, margin status, age, and medical comorbidities. This information can help with prognostication and potentially aid in treatment decision-making.</description><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Disease</subject><subject>Duodenal Neoplasms</subject><subject>Gastroenterology</subject><subject>Histology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Intestine, Small - surgery</subject><subject>Lymphoma</subject><subject>Lymphoma - surgery</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neoplasm Staging</subject><subject>Original Article</subject><subject>Patients</subject><subject>Proportional Hazards Models</subject><subject>Rare diseases</subject><subject>Retrospective Studies</subject><subject>Small intestine</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Surgical outcomes</subject><subject>Womens health</subject><issn>1091-255X</issn><issn>1873-4626</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlb_gAdZ8CJIdJJsvo5a_IKKhyp4C9ndbG3Zj5p0kf57U7cqePA0A_PMO8OD0DGBCwIgLwMhAjgGChhSyQCzHTQkSjKcCip2Yw-aYMr56wAdhLAAIBKI2kcDRoUQqdZDdD7t_Gye2yp5tI2dudo1q6Qtk2ltqyq5bj9clUzW9fKtre0h2ittFdzRto7Qy-3N8_geT57uHsZXE5wzyVfYOqBUKJ1lnEihhJbAQXEmWVpSBVnOSQGc5BmjXJWKcCuyjBU8d7wswHI2Qmd97tK3750LK1PPQ-6qyjau7YKhKU1BS64goqd_0EXb-SZ-FymtpBaSbyjaU7lvQ_CuNEs_r61fGwJmo9L0Kk1Uab5UGhaXTrbRXVa74mfl210EWA-EOGpmzv_e_if2E-A1e0o</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Lu, Pamela W.</creator><creator>Fields, Adam C.</creator><creator>Yoo, James</creator><creator>Irani, Jennifer</creator><creator>Goldberg, Joel E.</creator><creator>Bleday, Ronald</creator><creator>Melnitchouk, Nelya</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4960-3753</orcidid></search><sort><creationdate>20210301</creationdate><title>Surgical Management of Small Bowel Lymphoma</title><author>Lu, Pamela W. ; Fields, Adam C. ; Yoo, James ; Irani, Jennifer ; Goldberg, Joel E. ; Bleday, Ronald ; Melnitchouk, Nelya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-ae022689bb51768697050853734f280bc51d051cb3258f815a6bb3d5ce5fd0a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Disease</topic><topic>Duodenal Neoplasms</topic><topic>Gastroenterology</topic><topic>Histology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Intestine, Small - surgery</topic><topic>Lymphoma</topic><topic>Lymphoma - surgery</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neoplasm Staging</topic><topic>Original Article</topic><topic>Patients</topic><topic>Proportional Hazards Models</topic><topic>Rare diseases</topic><topic>Retrospective Studies</topic><topic>Small intestine</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Surgical outcomes</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Pamela W.</creatorcontrib><creatorcontrib>Fields, Adam C.</creatorcontrib><creatorcontrib>Yoo, James</creatorcontrib><creatorcontrib>Irani, Jennifer</creatorcontrib><creatorcontrib>Goldberg, Joel E.</creatorcontrib><creatorcontrib>Bleday, Ronald</creatorcontrib><creatorcontrib>Melnitchouk, Nelya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastrointestinal surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Pamela W.</au><au>Fields, Adam C.</au><au>Yoo, James</au><au>Irani, Jennifer</au><au>Goldberg, Joel E.</au><au>Bleday, Ronald</au><au>Melnitchouk, Nelya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Surgical Management of Small Bowel Lymphoma</atitle><jtitle>Journal of gastrointestinal surgery</jtitle><stitle>J Gastrointest Surg</stitle><addtitle>J Gastrointest Surg</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>25</volume><issue>3</issue><spage>757</spage><epage>765</epage><pages>757-765</pages><issn>1091-255X</issn><eissn>1873-4626</eissn><abstract>Background Primary small bowel non-Hodgkin’s lymphoma is a rare disease representing 2% of small intestine malignancies. There is limited data delineating the optimal treatment for these heterogeneous tumors. We aim to examine relationships between different treatment modalities and surgical outcomes in patients with small bowel lymphoma. Materials and Methods Patients diagnosed with stage I–III small bowel lymphoma in 2004–2015 who underwent surgery were identified in the National Cancer Database. Two cohorts were created based on systemic chemotherapy treatment status. The primary outcome was overall survival. An adjusted Cox proportional hazards model was used to evaluate the impact of treatment strategy on survival. Results 2283 patients met inclusion criteria Of these patients, 826 patients (36%) underwent surgical resection alone, and 1457 patients (64%) underwent resection with systemic chemotherapy. Chemotherapy was associated with improved overall survival in unadjusted (5-year overall survival, 55% versus 70%) and adjusted analysis (HR 0.54, 95% CI 0.47–0.63, p  &lt; 0.001). Discussion Patients with small bowel lymphoma have a low five-year overall survival after surgery. Chemotherapy is associated with improved survival, although one third of patients do not receive this therapy. Several other clinical factors are identified that are also associated with overall survival, including histology subtype, margin status, age, and medical comorbidities. This information can help with prognostication and potentially aid in treatment decision-making.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32666499</pmid><doi>10.1007/s11605-020-04730-3</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4960-3753</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1091-255X
ispartof Journal of gastrointestinal surgery, 2021-03, Vol.25 (3), p.757-765
issn 1091-255X
1873-4626
language eng
recordid cdi_proquest_miscellaneous_2424097580
source Springer Nature
subjects Cancer therapies
Chemotherapy
Disease
Duodenal Neoplasms
Gastroenterology
Histology
Hospitals
Humans
Intestine, Small - surgery
Lymphoma
Lymphoma - surgery
Medical diagnosis
Medicine
Medicine & Public Health
Neoplasm Staging
Original Article
Patients
Proportional Hazards Models
Rare diseases
Retrospective Studies
Small intestine
Statistical analysis
Surgery
Surgical outcomes
Womens health
title Surgical Management of Small Bowel Lymphoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T10%3A57%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Surgical%20Management%20of%20Small%20Bowel%20Lymphoma&rft.jtitle=Journal%20of%20gastrointestinal%20surgery&rft.au=Lu,%20Pamela%20W.&rft.date=2021-03-01&rft.volume=25&rft.issue=3&rft.spage=757&rft.epage=765&rft.pages=757-765&rft.issn=1091-255X&rft.eissn=1873-4626&rft_id=info:doi/10.1007/s11605-020-04730-3&rft_dat=%3Cproquest_cross%3E2498796750%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-ae022689bb51768697050853734f280bc51d051cb3258f815a6bb3d5ce5fd0a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2498796750&rft_id=info:pmid/32666499&rfr_iscdi=true